- Home
- IMRX
as of 03-06-2026 3:57pm EST
$5.32
+$0.34
+6.87%
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 322.8M | IPO Year: | 2021 |
| Target Price: | $17.20 | AVG Volume (30 days): | 687.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | 37.75 |
| 52 Week Low/High: | $1.10 - $10.08 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -4.13 | Index: | N/A |
| Free Cash Flow: | -45486821.0 | FCF Growth: | N/A |
AI-Powered IMRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.84%
74.84%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immuneering Corporation (IMRX)
Brakewood Harold Eugene
Buy
Chief Business Officer
IMRX Jan 16, 2026
Avg Cost/Share
$4.76
Shares
5,250
Total Value
$24,990.00
Owned After
11,050
SEC Form 4
Schall Thomas J.
Buy
Director
IMRX Jan 15, 2026
Avg Cost/Share
$4.67
Shares
21,645
Total Value
$101,041.02
Owned After
74,530
SEC Form 4
Hall Brett Matthew
Buy
CHIEF SCIENTIFIC OFFICER
IMRX Jan 15, 2026
Avg Cost/Share
$4.57
Shares
2,298
Total Value
$10,501.86
Owned After
376,496
SEC Form 4
Neufeld Leah R
Buy
CHIEF PEOPLE OFFICER
IMRX Jan 13, 2026
Avg Cost/Share
$4.15
Shares
2,626
Total Value
$10,905.78
Owned After
25,970
SEC Form 4
Feinberg Peter
Buy
Director
IMRX Jan 12, 2026
Avg Cost/Share
$4.35
Shares
20,000
Total Value
$86,904.00
Owned After
135,441
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Brakewood Harold Eugene | IMRX | Chief Business Officer | Jan 16, 2026 | Buy | $4.76 | 5,250 | $24,990.00 | 11,050 | |
| Schall Thomas J. | IMRX | Director | Jan 15, 2026 | Buy | $4.67 | 21,645 | $101,041.02 | 74,530 | |
| Hall Brett Matthew | IMRX | CHIEF SCIENTIFIC OFFICER | Jan 15, 2026 | Buy | $4.57 | 2,298 | $10,501.86 | 376,496 | |
| Neufeld Leah R | IMRX | CHIEF PEOPLE OFFICER | Jan 13, 2026 | Buy | $4.15 | 2,626 | $10,905.78 | 25,970 | |
| Feinberg Peter | IMRX | Director | Jan 12, 2026 | Buy | $4.35 | 20,000 | $86,904.00 | 135,441 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 6, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 6, 2026 · 100% conf.
AI Prediction BUY
1D
+2.66%
$5.29
5D
+15.42%
$5.94
20D
+35.74%
$6.99
Price: $5.15 Prob +5D: 100% AUC: 1.000
0001790340-26-000040
imrx-202603060001790340FALSE00017903402026-03-062026-03-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026
Immuneering Corporation (Exact name of Registrant as Specified in Its Charter)
Delaware001-4067526-1976972 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
245 Main St. Second Floor Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) (617) 500-8080 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.001 per shareIMRXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On March 6, 2026, Immuneering Corporation (the “Company”) announced its financial results for the quarter and the full-year ended December 31, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”). The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:
Exhibit No.Description 99.1Press Release issued on March 6, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNEERING CORPORATION
Date: March 6, 2026 By: /s/ Benjamin J. Zeskind Name: Benjamin J. Zeskind, Ph.D. Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 12, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K BUYNov 12, 2025 · 100% conf.
AI Prediction BUY
1D
+3.40%
$6.85
5D
+16.43%
$7.71
20D
+41.75%
$9.38
Price: $6.62 Prob +5D: 100% AUC: 1.000
0001790340-25-000133
imrx-202511120001790340FALSE00017903402025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025
Immuneering Corporation (Exact name of Registrant as Specified in Its Charter)
Delaware001-4067526-1976972 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
245 Main St. Second Floor Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) (617) 500-8080 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.001 per shareIMRXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 12, 2025, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”). The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:
Exhibit No.Description 99.1Press Release issued on November 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNEERING CORPORATION
Date: November 12, 2025 By: /s/ Benjamin J. Zeskind Name: Benjamin J. Zeskind, Ph.D. Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 13, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 13, 2025
0001790340-25-000102
imrx-202508130001790340FALSE00017903402025-08-132025-08-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025
Immuneering Corporation (Exact name of Registrant as Specified in Its Charter)
Delaware001-4067526-1976972 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
245 Main St. Second Floor Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) (617) 500-8080 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Class A common stock, par value $0.001 per shareIMRXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On August 13, 2025, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”). The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits. (d)Exhibits The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:
Exhibit No.Description 99.1Press Release issued on August 13, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNEERING CORPORATION
Date: August 13, 2025 By: /s/ Benjamin J. Zeskind Name: Benjamin J. Zeskind, Ph.D. Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)
Latest Immuneering Corporation News
IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing
Compare IMRX vs Leading Stocks
See how IMRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.